Transition Plans for Covid-19 Products are Amongst CDRH FY2023 Priorities
FDA Law
OCTOBER 18, 2022
Also part of FDA’s FY2023 guidance document plan is a retrospective review of guidance documents issued in 1993, 2003, and 2013. The 2013 guidance documents include, but are not limited to, in vitro diagnostic and clinical trial considerations. electronic thermometers, single lumen needles, piston syringes).
Let's personalize your content